Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer Allen JA; Adlakha A; Bergethon PRArch Neurol 2006[Oct]; 63 (10): 1475-8OBJECTIVE: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor. DESIGN: Case report/literature review. SETTING: University hospital. PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma. RESULTS: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab. CONCLUSIONS: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.|Angiogenesis Inhibitors/adverse effects[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*adverse effects[MESH]|Antineoplastic Combined Chemotherapy Protocols/*adverse effects[MESH]|Aphasia/chemically induced/physiopathology[MESH]|Bevacizumab[MESH]|Blindness, Cortical/chemically induced/physiopathology[MESH]|Blood Vessels/drug effects/physiopathology[MESH]|Camptothecin/adverse effects/analogs & derivatives[MESH]|Carcinoma/blood supply/*drug therapy/secondary[MESH]|Cognition Disorders/chemically induced/physiopathology[MESH]|Colonic Neoplasms/blood supply/*drug therapy/pathology[MESH]|Dementia, Vascular/*chemically induced/physiopathology[MESH]|Fluorouracil/adverse effects[MESH]|Humans[MESH]|Leucovorin/adverse effects[MESH]|Liver Neoplasms/blood supply/*drug therapy/secondary[MESH]|Magnetic Resonance Imaging[MESH]|Male[MESH]|Middle Aged[MESH]|Neovascularization, Pathologic/drug therapy/physiopathology[MESH]|Occipital Lobe/*drug effects/pathology/physiopathology[MESH]|Parietal Lobe/drug effects/pathology/physiopathology[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism[MESH] |
